Sarepta Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Sarepta Therapeutics (SRPT).

Price Target Range — 7 Quarters

Analyst Consensus — 24 Analysts

9Buy

10Hold

5Sell

Consensus RatingOutperform# Analysts24Avg. Consensus PT$25Upside to Avg. PT+30.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Cut	Sector Perform	$19→$17
Oct 5, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Sell	$5
Sep 30, 2026	JP Morgan	Anupam Rama	PT Cut	Neutral	$23→$20
Sep 28, 2026	Needham	Gil Blum	Maintained	Underperform	—
Jul 9, 2026	Piper Sandler	Biren Amin	PT Cut	Neutral	$23→$20
Jul 9, 2026	Wolfe Research	Andy Chen	Upgrade	Peer Perform→Outperform	$27
Apr 16, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Sell	$5
Mar 26, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Sell	$9→$13
Mar 26, 2026	Needham	Gil Blum	Maintained	Underperform	—
Mar 19, 2026	Oppenheimer	Kostas Biliouris	Maintained	Outperform	$37
Mar 13, 2026	Mizuho	Uy Ear	PT Raise	Outperform	$26→$31
Mar 10, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Sell	$8→$9
Mar 2, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Sell	$5
Feb 27, 2026	Wells Fargo	Yanan Zhu	PT Cut	Overweight	$45→$38
Jan 27, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Sell	$5
Jan 23, 2026	Wedbush	Yun Zhong	PT Raise	Outperform	$32→$34
Jan 14, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Sell	$5
Dec 9, 2025	Wedbush	Yun Zhong	Initiate	Outperform	$32
Nov 5, 2025	Barclays	Gena Wang	PT Cut	Equal-Weight	$22→$20
Nov 5, 2025	Wells Fargo	Yanan Zhu	PT Cut	Overweight	$50→$45

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $17

RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sector Perform and lowers the price target from $19 to $17.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.

Benzinga Newsdesk

PRO
JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.

Benzinga Newsdesk

PRO
Needham Reiterates Underperform on Sarepta Therapeuticsto Underperform

Needham analyst Gil Blum reiterates Sarepta Therapeutics (NASDAQ:SRPT) from Underperform to Underperform.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.

Benzinga Newsdesk

PRO
Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price Target

Wolfe Research analyst Andy Chen upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Peer Perform to Outperform and announces $27 price target.

Benzinga Newsdesk

Sarepta Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Sarepta Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $17

PRO
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target

PRO
JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

PRO
Needham Reiterates Underperform on Sarepta Therapeuticsto Underperform

PRO
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

PRO
Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price Target

People Also Watch

People Also Watch

Sarepta Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Sarepta Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $17

PROHC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target

PROJP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

PRONeedham Reiterates Underperform on Sarepta Therapeuticsto Underperform

PROPiper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

PROWolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price Target

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $17

PRO
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target

PRO
JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

PRO
Needham Reiterates Underperform on Sarepta Therapeuticsto Underperform

PRO
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

PRO
Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price Target